Skip to main content

Table 2 Overview and frequency of identified mutations in 27 patients (potentially treatment relevant mutations in italic)

From: Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi

Identified mutations (n)

NRTI

Accessory PI

NNRTI

Resistance level to EFVa

M184 (1)

T47S (7)

K103N (11)

High

 

Q58E (4)

A98G (3)

High level resistance 3TC, Low level resistance EFV

 

K20T (1)

V106M (2)

High

 

M46L (1)

Y181C (7)

Intermediate

 

M46V (1)

G190A (2)

Intermediate

 

N88D (1)

K103S (1)

Intermediate

  

K238T (1)

Intermediate

  

H221Y (4)

Low

  

V108I (4)

Low

  

E138G (2)

Low

  

V179D (2)

Low

  

E138K (1)

Low

  

K101E (1)

Low

  1. The total number of mutations reported is higher than the number of individual samples with NNRTI-DRMs, as many samples showed multiple mutations
  2. NRTI nucleoside/nucleotide reverse transcriptase inhibitors, PI protease inhibitors, NNRTI non-nucleoside reverse-transcriptase inhibitors, EFV efavirenz, 3TC lamivudine
  3. aAccording to the Stanford Drug Resistance Database